Sentence examples for mean difference per from inspiring English sources

However, beneficiaries' average daily MMEs of opioids were elevated during both lock-in and post-release (daily mean difference per person: 18.7 (95% CI: 13.9, 23.6); 11.1 (95% CI: 5.1, 17.1), respectively).

The SNP with the strongest effect (0.36 mmol/L mean difference per one T allele, 95% CI [0.21,0.52] mmol/L; rs2228671; red circle in Fig. 2a) was chosen for replication in further populations.

We then confirmed this association in the larger MONICA/KORA S4 study comprising 4 184 individuals with a mean difference per T allele of 0.20 mmol/L (95% CI [0.13 0.28] mmol/L; p = 2.6×10−8) and the population-based PopGen study comprising 2 458 individuals with a mean difference per T allele of 0.14 mmol/L (95% CI [0.06 0.23] mmol/L; p = 0.0012; Fig. 3a).

There was also some evidence that mother's BMI was more strongly associated with daughter's than with sons'subscapular skinfold thickness (mean difference per 1SD mothers BMI in daughters 0.15SD (95%CI: 0.12, 0.19) and in sons 0.12SD (0.15, 0.15), p for interaction  = 0.07), but again the magnitude of the difference was small.

A summary weighted mean difference per allele (minor allele) was calculated using fixed effects model by an inverse-variance method.

Home telemonitoring of BP costs significantly more than usual care (mean difference per patient £115.32 (95% CI £83.49 to £146.63; p<0.001)).

We also calculated the mean differences per patient (and 95% confidence intervals) between pairs of instruments to determine the extent of variation between the HUs.

In addition, at 12 weeks but not in earlier time points, there was significant improvement in change from baseline in the absolute CrCl values with mean differences per minute of 0.034 ± 0.04 ml in the hNPC group versus −0.0137 ± 0.019 ml/min in the untreated group (t-test, p = 0.01; Fig 4D).

For the SMM (double logistic SMM), results are presented as both the adjusted mean difference (OR) per % increase in adherence and per 100% adherence, the latter of which can be interpreted as the maximum possible efficacy.

As continuous treatment requires, on average, nine more injections (p<0.001), but avoids only six monitoring visits (p<0.001), drug administration and monitoring costs were higher with continuous treatment than discontinuous treatment (mean difference: £130 per patient ($20495 95% CI £20 to £239; p=0.021), with no significant difference between bevacizumab and ranibizumab (p=0.80).

Regarding sick leave, the mean difference in the per-protocol analysis between the BM programme and the control group was 201 days, thus reducing sick leave by about two-thirds of a working year.